Vir Biotechnology licenses three clinical-stage masked T-cell engagers from Sanofi for $100M upfront

Vir Biotechnology, Inc.

Upfront payment of $100M plus $75M escrowed milestone for SAR446368 (AMX-525) first-in-human dosing by 2026.
Eligible for up to $323M in development/regulatory milestones and up to $1.488B in commercial sales milestones.
License covers SAR446309, SAR446329, and SAR446368 (AMX-525) masked T-cell engagers and protease-cleavable masking platform.
Exclusive worldwide license for oncology and infectious disease, excluding ophthalmology; low single-digit to low double-digit tiered royalties.
Closing contingent on expiration or termination of applicable HSR waiting period.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.